文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

临床试验中的银屑病评估工具。

Psoriasis assessment tools in clinical trials.

作者信息

Feldman S R, Krueger G G

机构信息

Wake Forest University School of Medicine, Department of Dermatology, Winston-Salem, NC 27157-1071, USA.

出版信息

Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii65-8; discussion ii69-73. doi: 10.1136/ard.2004.031237.

DOI:10.1136/ard.2004.031237
PMID:15708941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1766877/
Abstract

In clinical practice, broad global assessments of psoriasis disease activity and its effect on patients' quality of life are used to assess the severity of patients' disease and their response to treatment. In clinical trials, more objective, validated instruments are required. Several such instruments have been developed and continue to be developed to provide an assessment of the severity of the skin lesions. Because a lesion's impact on patients' lives varies widely among patients, there has been growing recognition of the need to measure the quality of life impact of the disease along with the severity of the lesions.

摘要

在临床实践中，对银屑病疾病活动及其对患者生活质量的影响进行广泛的整体评估，以评估患者疾病的严重程度及其对治疗的反应。在临床试验中，则需要更客观、经过验证的工具。已经开发了几种这样的工具，并且仍在不断开发，以评估皮肤病变的严重程度。由于病变对患者生活的影响在患者之间差异很大，人们越来越认识到需要在测量病变严重程度的同时，衡量该疾病对生活质量的影响。

相似文献

[1]
Psoriasis assessment tools in clinical trials.

Ann Rheum Dis. 2005-3

[2]
Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative.

Am J Clin Dermatol. 2020-6

[3]
Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice.

Dermatol Clin. 2015-1

[4]
Psoriatic arthritis assessment tools in clinical trials.

Ann Rheum Dis. 2005-3

[5]
How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.

J Invest Dermatol. 2009-12-31

[6]
Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials.

Health Qual Life Outcomes. 2003-10-8

[7]
Clinical outcome measures of psoriasis.

Reumatismo. 2007

[8]
Treatment Goals in Psoriasis: Which Outcomes Matter Most?

Am J Clin Dermatol. 2020-8

[9]
The outcomes movement and new measures of the severity of psoriasis.

J Am Acad Dermatol. 1996-3

[10]
Biologics are more potent than other treatment modalities for improvement of quality of life in psoriasis patients.

J Dermatol. 2014-8

引用本文的文献

[1]
Development and Validation of an Artificial Intelligence-Driven Model for Accurate Classification of Erythrodermic Psoriasis Severity: Erythrodermic Psoriasis Integrated Classification System (EPICS).

Am J Clin Dermatol. 2025-8-26

[2]
Relative sensitivity and preference of indicators in pharmaceutical trials of psoriasis and psoriatic arthritis.

Eur J Med Res. 2025-8-26

[3]
Effect of Methotrexate on Semen Parameters in Psoriatic Male Patients.

Cureus. 2025-6-11

[4]
Longer Drug Retention of Interleukin-12/23 or Interleukin-17 Inhibitors Compared With TNF Inhibitors in Female Patients With TNF Inhibitor-Experienced Psoriatic Arthritis.

Mayo Clin Proc Innov Qual Outcomes. 2025-5-12

[5]
Can Circulating MicroRNAs, Cytokines, and Adipokines Help to Differentiate Psoriatic Arthritis from Erosive Osteoarthritis of the Hand? A Case-Control Study.

Int J Mol Sci. 2025-5-12

[6]
Best Responders and Super-Responders to Calcipotriol and Betamethasone Dipropionate PAD-Cream: A Post Hoc Pooled Analysis of Two Phase 3 Trials.

Dermatol Ther (Heidelb). 2025-6

[7]
Determinants of perceived patient benefit in a longitudinal cohort study of patients with psoriasis and atopic dermatitis.

Sci Rep. 2025-1-10

[8]
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis.

Dermatol Ther (Heidelb). 2024-10

[9]
Exploring the Correlation between the PASI and DLQI Scores in Psoriasis Treatment with Topical Ointments Containing Mill. Extract.

Pharmaceuticals (Basel). 2024-8-20

[10]
Biomarkers in Psoriasis: The Future of Personalised Treatment.

Indian J Dermatol. 2024

本文引用的文献

[1]
Psoriasis clinical registries, genetics, and genomics.

Ann Rheum Dis. 2005-3

[2]
Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment.

J Am Acad Dermatol. 2004-10

[3]
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.

J Am Acad Dermatol. 2004-6

[4]
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

JAMA. 2003-12-17

[5]
A randomized trial of etanercept as monotherapy for psoriasis.

Arch Dermatol. 2003-12

[6]
Etanercept as monotherapy in patients with psoriasis.

N Engl J Med. 2003-11-20

[7]
Infliximab for psoriasis.

J Am Acad Dermatol. 2003-8

[8]
The design of clinical trials in psoriasis: lessons for clinical practice.

J Am Acad Dermatol. 2003-8

[9]
The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison.

J Drugs Dermatol. 2003-6

[10]
Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis.

J Am Acad Dermatol. 2003-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索